Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06170294 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 14, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.
Trial Details
NCT Number NCT06170294
Lead Sponsor Peking University
Collaborators: Shanghai Ming Ju Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Advanced Solid Tumor
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov